{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:17:04Z","timestamp":1790644624190,"version":"4.1.0"},"reference-count":139,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T00:00:00Z","timestamp":1701129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Mast cell disorders range from benign proliferations to systemic diseases that cause anaphylaxis and other diverse symptoms to mast cell neoplasms with varied clinical outcomes. Mastocytosis is the pathologic process of the accumulation of abnormal mast cells in different organs, mostly driven by KIT mutations, and can present as cutaneous mastocytosis, systemic mastocytosis (SM), and mast cell sarcoma. The WHO 5th edition classification divides systemic mastocytosis into bone marrow mastocytosis, indolent systemic mastocytosis, smoldering systemic mastocytosis, aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, and mast cell leukemia. The new ICC classifies SM slightly differently. The diagnosis of SM requires the integration of bone marrow morphologic, immunophenotypic, and molecular findings, as well as clinical signs and symptoms. Moreover, understanding the wide range of clinical presentations for patients with mast cell disorders is necessary for accurate and timely diagnosis. This review provides an updated overview of mast cell disorders, with a special emphasis on SM, including the latest approaches to diagnosis, prognostic stratification, and management of this rare disease.<\/jats:p>","DOI":"10.3390\/cancers15235626","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T03:53:52Z","timestamp":1701230032000},"page":"5626","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Review and Updates on Systemic Mastocytosis and Related Entities"],"prefix":"10.3390","volume":"15","author":[{"given":"Julie Y.","family":"Li","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Ryder","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9034-0273","authenticated-orcid":false,"given":"Samuel G.","family":"Cockey","sequence":"additional","affiliation":[{"name":"Morsani College of Medicine, University of South Florida Health, Tampa, FL 33602, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Hyjek","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn C.","family":"Moscinski","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sagatys","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinming","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, H. Lee Moffitt Cancer Center, Tampa, FL 33612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,11,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Valent, P., Akin, C., Nedoszytko, B., Bonadonna, P., Hartmann, K., Niedoszytko, M., Brockow, K., Siebenhaar, F., Triggiani, M., and Arock, M. (2020). Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239030"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.iac.2018.04.003","article-title":"Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features","volume":"38","author":"Lyons","year":"2018","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1158\/0008-5472.CAN-16-2234","article-title":"Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future","volume":"77","author":"Valent","year":"2017","journal-title":"Cancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: A consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","article-title":"Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal","volume":"5","author":"Valent","year":"2021","journal-title":"Hemasphere"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: Integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: Consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur. J. Clin. Investig."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.4049\/jimmunol.174.2.1063","article-title":"Mast cells, basophils, and eosinophils acquire constitutive IL-4 and IL-13 transcripts during lineage differentiation that are sufficient for rapid cytokine production","volume":"174","author":"Gessner","year":"2005","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1182\/blood-2003-08-2769","article-title":"NTAL phosphorylation is a pivotal link between the signaling cascades leading to human mast cell degranulation following Kit activation and Fc epsilon RI aggregation","volume":"104","author":"Tkaczyk","year":"2004","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/978-1-4939-1568-2_15","article-title":"Fc\u03b5RI expression and dynamics on mast cells","volume":"1220","author":"Rios","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7150\/ijbs.6087","article-title":"The C-kit receptor-mediated signal transduction and tumor-related diseases","volume":"9","author":"Liang","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.jaci.2022.04.012","article-title":"KIT as a master regulator of the mast cell lineage","volume":"149","author":"Tsai","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.pai.0000173054.83414.22","article-title":"KIT (CD117): A review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation","volume":"13","author":"Miettinen","year":"2005","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: State of the art","volume":"122","author":"Valent","year":"2003","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"533","DOI":"10.5114\/aoms.2012.29534","article-title":"Mastocytosis in children and adults: Clinical disease heterogeneity","volume":"8","author":"Lange","year":"2012","journal-title":"Arch. Med. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000328760","article-title":"Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal","volume":"157","author":"Valent","year":"2012","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_22","first-page":"1493","article-title":"Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: Identification and enumeration","volume":"149","author":"Orfao","year":"1996","journal-title":"Am. J. Pathol."},{"key":"ref_23","unstructured":"Fong, M., and Crane, J.S. (2023). StatPearls, StatPearls."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2559.1979.tb03017.x","article-title":"Mast cells and mast cell neoplasia: A review","volume":"3","author":"Lennert","year":"1979","journal-title":"Histopathology"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"El Hussein, S., Chifotides, H.T., Khoury, J.D., Verstovsek, S., and Thakral, B. (2022). Systemic Mastocytosis and Other Entities Involving Mast Cells: A Practical Review and Update. Cancers, 14.","DOI":"10.3390\/cancers14143474"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaci.2017.06.007","article-title":"Mast cell activation syndromes","volume":"140","author":"Akin","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_27","unstructured":"National Comprehensive Cancer Network (2023, September 14). Systemic Mastocytosis. Available online: https:\/\/www.nccn.org\/login?ReturnURL=https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/mpn.pdf."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1056\/NEJMcp1412282","article-title":"Clinical practice. Allergic rhinitis","volume":"372","author":"Wheatley","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1056\/NEJMra1409760","article-title":"Mast Cells, Mastocytosis, and Related Disorders","volume":"373","author":"Theoharides","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.jaip.2019.01.006","article-title":"Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome","volume":"7","author":"Valent","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1159\/000524532","article-title":"Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022","volume":"183","author":"Valent","year":"2022","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.jaci.2019.08.023","article-title":"AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management","volume":"144","author":"Weiler","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00428-022-03423-3","article-title":"The international consensus classification of mastocytosis and related entities","volume":"482","author":"Leguit","year":"2023","journal-title":"Virchows Arch."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.jaci.2022.04.004","article-title":"Clinical impact and proposed application of molecular markers, genetic variants, and cytogenetic analysis in mast cell neoplasms: Status 2022","volume":"149","author":"Arock","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.iac.2006.05.010","article-title":"Diagnostic value of tryptase in anaphylaxis and mastocytosis","volume":"26","author":"Schwartz","year":"2006","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJM198706253162603","article-title":"Tryptase Levels as an Indicator of Mast-Cell Activation in Systemic Anaphylaxis and Mastocytosis","volume":"316","author":"Schwartz","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.advms.2017.12.003","article-title":"Markers of anaphylaxis\u2014A systematic review","volume":"63","author":"Klimek","year":"2018","journal-title":"Adv. Med. Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1016\/j.jaip.2020.02.021","article-title":"The Utility of Measuring Urinary Metabolites of Mast Cell Mediators in Systemic Mastocytosis and Mast Cell Activation Syndrome","volume":"8","author":"Butterfield","year":"2020","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/ng.3696","article-title":"Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number","volume":"48","author":"Lyons","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.anai.2021.08.009","article-title":"Clinical relevance of inherited genetic differences in human tryptases: Hereditary alpha-tryptasemia and beyond","volume":"127","author":"Glover","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.2020006157","article-title":"Hereditary alpha tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis","volume":"137","author":"Greiner","year":"2021","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jaci.2021.06.017","article-title":"Hereditary alpha tryptasemia is not associated with specific clinical phenotypes","volume":"149","author":"Chollet","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.jaip.2022.05.003","article-title":"Incorporating Tryptase Genotyping into the Workup and Diagnosis of Mast Cell Diseases and Reactions","volume":"10","author":"Lyons","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","article-title":"Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1","volume":"147","author":"Lyons","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","article-title":"Epidemiology, prognosis, and risk factors in mastocytosis","volume":"34","author":"Brockow","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12016-017-8619-2","article-title":"Mastocytosis: From a Molecular Point of View","volume":"54","author":"Komi","year":"2018","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Valent, P., Akin, C., Gleixner, K.V., Sperr, W.R., Reiter, A., Arock, M., and Triggiani, M. (2019). Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122976"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"E209","DOI":"10.1002\/ajh.26963","article-title":"ICC-2022 versus WHO-2022 classification systems for acute leukemias and myeloid neoplasms: The perspective from two classical morphologists","volume":"98","author":"Zini","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_49","unstructured":"WHO Classification of Tumours Editorial Board (2022). Hematolymphoid Tumors, International Agency for Research Cancer. Available online: https:\/\/tumourclassification.iarc.who.int."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/ajh.26962","article-title":"Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management","volume":"98","author":"Pardanani","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/j.1525-1470.2008.00738.x","article-title":"Mastocytosis in children: A protocol for management","volume":"25","author":"Heide","year":"2008","journal-title":"Pediatr. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.18632\/oncotarget.4213","article-title":"Mastocytosis: A mutated KIT receptor induced myeloproliferative disorder","volume":"6","author":"Chatterjee","year":"2015","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e2021046","DOI":"10.4084\/MJHID.2021.046","article-title":"Systemic Mastocytosis: Molecular Landscape and Implications for Treatment","volume":"13","author":"Monaldi","year":"2021","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood.2018886507","article-title":"Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis","volume":"134","author":"Henriques","year":"2019","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jaci.2015.05.008","article-title":"Clinical, immunophenotypic, and molecular characteristics of well-differentiated systemic mastocytosis","volume":"137","author":"Morgado","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"68950","DOI":"10.18632\/oncotarget.10711","article-title":"Imatinib in systemic mastocytosis: A phase IV clinical trial in patients lacking exon 17 KIT mutations and review of the literature","volume":"8","author":"Matito","year":"2017","journal-title":"Oncotarget"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/bjh.13865","article-title":"ASXL1 and CBL mutations are independently predictive of inferior survival in advanced systemic mastocytosis","volume":"175","author":"Pardanani","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1182\/bloodadvances.2018020628","article-title":"Impact of somatic and germline mutations on the outcome of systemic mastocytosis","volume":"2","author":"Merker","year":"2018","journal-title":"Blood Adv."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2015.284","article-title":"Additional mutations in SRSF2, ASXL1 and\/or RUNX1 identify a high-risk group of patients with KIT D816V(+) advanced systemic mastocytosis","volume":"30","author":"Jawhar","year":"2016","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/ajh.25265","article-title":"Cytogenetic abnormalities in systemic mastocytosis: WHO subcategory-specific incidence and prognostic impact among 348 informative cases","volume":"93","author":"Shah","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/gcc.22526","article-title":"Incidence and prognostic impact of cytogenetic aberrations in patients with systemic mastocytosis","volume":"57","author":"Naumann","year":"2018","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.iac.2013.09.001","article-title":"Mastocytosis","volume":"34","author":"Carter","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/joim.12410","article-title":"Mastocytosis: The puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease","volume":"279","author":"Nilsson","year":"2016","journal-title":"J. Intern. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jaip.2013.09.004","article-title":"The Mastocytosis Society survey on mast cell disorders: Patient experiences and perceptions","volume":"2","author":"Jennings","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_68","first-page":"77","article-title":"Novel approaches to treating advanced systemic mastocytosis","volume":"11","author":"Gilreath","year":"2019","journal-title":"Clin. Pharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/hematology.2022000366","article-title":"How to evaluate the patient with a suspected mast cell disorder and how\/when to manage symptoms","volume":"2022","author":"Akin","year":"2022","journal-title":"Hematology Am. Soc. Hematol. Educ. Program."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1309\/AJCP1Q0YSXEAHNKK","article-title":"Hidden mastocytosis in acute myeloid leukemia with t(8;21)(q22;q22)","volume":"140","author":"Johnson","year":"2013","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1182\/blood-2009-10-249979","article-title":"WHO subvariants of indolent mastocytosis: Clinical details and prognostic evaluation in 159 consecutive adults","volume":"115","author":"Pardanani","year":"2010","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/ajh.26118","article-title":"Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management","volume":"96","author":"Pardanani","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"482","DOI":"10.3324\/haematol.2010.034553","article-title":"Isolated bone marrow mastocytosis: An underestimated subvariant of indolent systemic mastocytosis","volume":"96","author":"Zanotti","year":"2011","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaci.2013.06.020","article-title":"Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM","volume":"133","author":"Zanotti","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/ACI.0b013e32833b280c","article-title":"Mastocytosis and insect venom allergy","volume":"10","author":"Bonadonna","year":"2010","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood-2006-06-028100","article-title":"Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with \u201cidiopathic\u201d anaphylaxis","volume":"110","author":"Akin","year":"2007","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaci.2008.11.018","article-title":"Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels","volume":"123","author":"Bonadonna","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MOH.0000000000000486","article-title":"Novel Approaches for Systemic Mastocytosis","volume":"26","author":"Fletcher","year":"2019","journal-title":"Curr. Opin. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/all.14248","article-title":"Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification","volume":"75","author":"Trizuljak","year":"2020","journal-title":"Allergy"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Zanotti, R., Tanasi, I., Bernardelli, A., Orsolini, G., and Bonadonna, P. (2021). Bone Marrow Mastocytosis: A Diagnostic Challenge. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071420"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jaci.2009.05.003","article-title":"Prognosis in adult indolent systemic mastocytosis: A long-term study of the Spanish Network on Mastocytosis in a series of 145 patients","volume":"124","author":"Escribano","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e638","DOI":"10.1016\/S2352-3026(19)30166-8","article-title":"International prognostic scoring system for mastocytosis (IPSM): A retrospective cohort study","volume":"6","author":"Sperr","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41375-021-01406-y","article-title":"Refined diagnostic criteria for bone marrow mastocytosis: A proposal of the European competence network on mastocytosis","volume":"36","author":"Zanotti","year":"2022","journal-title":"Leukemia"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1002\/ajh.25302","article-title":"Smoldering mastocytosis: Survival comparisons with indolent and aggressive mastocytosis","volume":"94","author":"Tefferi","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000504099","article-title":"The Spectrum of Aggressive Mastocytosis: A Workshop Report and Literature Review","volume":"87","author":"Leguit","year":"2020","journal-title":"Pathobiology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1093\/annonc\/mdu047","article-title":"Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): A consensus proposal","volume":"25","author":"Valent","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/leu.2015.4","article-title":"Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event","volume":"29","author":"Jawhar","year":"2015","journal-title":"Leukemia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.23380","article-title":"Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: Clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components","volume":"88","author":"Wang","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Lhermitte","year":"2013","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2014.09.010","article-title":"Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features","volume":"39","author":"Valent","year":"2015","journal-title":"Leuk. Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.leukres.2017.05.018","article-title":"Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome","volume":"59","author":"Jain","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.leukres.2019.01.005","article-title":"A registry-based analysis of survival outcomes in mast cell leukemia","volume":"78","author":"Budnik","year":"2019","journal-title":"Leuk. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jaci.2021.08.007","article-title":"Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis","volume":"149","author":"Mateja","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/modpathol.2012.199","article-title":"Mast cell sarcoma: A rare and potentially under-recognized diagnostic entity with specific therapeutic implications","volume":"26","author":"Ryan","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1309\/AJCPSGQ71GJQQACL","article-title":"Morphologically occult systemic mastocytosis in bone marrow: Clinicopathologic features and an algorithmic approach to diagnosis","volume":"144","author":"Reichard","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.iac.2014.01.005","article-title":"Mastocytosis: Immunophenotypical features of the transformed mast cells are unique among hematopoietic cells","volume":"34","author":"Horny","year":"2014","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1097\/01.pas.0000138181.89743.7b","article-title":"CD25 indicates the neoplastic phenotype of mast cells: A novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens","volume":"28","author":"Sotlar","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/cyto.b.21336","article-title":"Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis","volume":"90","author":"Cherian","year":"2016","journal-title":"Cytom. Part B Clin. Cytom."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: Prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/leu.2015.348","article-title":"CD123 immunostaining patterns in systemic mastocytosis: Differential expression in disease subgroups and potential prognostic value","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1373\/clinchem.2017.277897","article-title":"Digital PCR: A Sensitive and Precise Method for KIT D816V Quantification in Mastocytosis","volume":"64","author":"Greiner","year":"2018","journal-title":"Clin. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J. Mol. Diagn."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/all.12920","article-title":"Patient-reported disease-specific quality-of-life and symptom severity in systemic mastocytosis","volume":"71","author":"Safy","year":"2016","journal-title":"Allergy"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2013-01-453183","article-title":"How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage)","volume":"121","author":"Pardanani","year":"2013","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1080\/10428194.2019.1703974","article-title":"New developments in the field of mastocytosis and mast cell activation syndromes: A summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019","volume":"61","author":"Arock","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/all.13237","article-title":"Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations","volume":"73","author":"Vestergaard","year":"2018","journal-title":"Allergy"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM200402123500723","article-title":"Leukotriene-receptor inhibition for the treatment of systemic mastocytosis","volume":"350","author":"Tolar","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1182\/asheducation-2015.1.98","article-title":"Diagnosis and management of mastocytosis: An emerging challenge in applied hematology","volume":"2015","author":"Valent","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0091-6749(90)90067-E","article-title":"Cromolyn sodium in the management of systemic mastocytosis","volume":"85","author":"Horan","year":"1990","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2133.2009.09516.x","article-title":"Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus","volume":"162","author":"Magerl","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1056\/NEJM197908303010903","article-title":"Oral disodium cromoglycate in the treatment of systemic mastocytosis","volume":"301","author":"Soter","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0889-8588(05)70301-4","article-title":"Treatment of systemic mast cell disorders","volume":"14","author":"Worobec","year":"2000","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1517\/14656566.2013.824424","article-title":"Mastocytosis: Update on pharmacotherapy and future directions","volume":"14","author":"Cardet","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jaip.2019.03.039","article-title":"Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS","volume":"7","author":"Lemal","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1136\/ard.2009.124511","article-title":"Systemic mastocytosis and bone involvement in a cohort of 75 patients","volume":"69","author":"Barete","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/cea.13592","article-title":"Omalizumab in the treatment of adult patients with mastocytosis: A systematic review","volume":"50","author":"Jendoubi","year":"2020","journal-title":"Clin. Exp. Allergy"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Teodosio","year":"2006","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jaci.2018.06.003","article-title":"Midostaurin in patients with indolent systemic mastocytosis: An open-label phase 2 trial","volume":"142","author":"Span","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1002\/ajh.24553","article-title":"Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management","volume":"91","author":"Pardanani","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2133.1995.tb08689.x","article-title":"Interferon-alpha in combination with corticosteroids improves systemic mast cell disease","volume":"132","author":"Delaporte","year":"1995","journal-title":"Br. J. Dermatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e2022073","DOI":"10.4084\/MJHID.2022.073","article-title":"Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management","volume":"14","author":"Papayannidis","year":"2022","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1182\/blood-2014-12-614743","article-title":"Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis","volume":"126","author":"Barete","year":"2015","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis","volume":"102","author":"Oldhoff","year":"2003","journal-title":"Blood"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2015-06-649525","article-title":"Cladribine for mastocytosis: Benefits and risks","volume":"126","author":"Akin","year":"2015","journal-title":"Blood"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1093\/annonc\/mdx290","article-title":"Midostaurin: A magic bullet that blocks mast cell expansion and activation","volume":"28","author":"Valent","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/01.HS9.0000561600.89121.38","article-title":"S830 Avapritinib, a Potent and Selective Inhibitor of Kit D816V, Induces Complete and Durable Responses in Patients (PTS) with Advanced Systemic Mastocytosis (ADVSM)","volume":"3","author":"Radia","year":"2019","journal-title":"HemaSphere"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Scium\u00e8, M., De Magistris, C., Galli, N., Ferretti, E., Milesi, G., De Roberto, P., Fabris, S., and Grifoni, F.I. (2022). Target Therapies for Systemic Mastocytosis: An Update. Pharmaceuticals, 15.","DOI":"10.3390\/ph15060738"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-021-01538-9","article-title":"Safety and efficacy of avapritinib in advanced systemic mastocytosis: The phase 1 EXPLORER trial","volume":"27","author":"DeAngelo","year":"2021","journal-title":"Nat. Med."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/17474086.2021.1959315","article-title":"Avapritinib for Systemic Mastocytosis","volume":"14","author":"Bose","year":"2021","journal-title":"Expert. Rev. Hematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.bbmt.2016.04.018","article-title":"Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis","volume":"22","author":"Ustun","year":"2016","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1200\/JCO.2014.55.2018","article-title":"Hematopoietic stem-cell transplantation for advanced systemic mastocytosis","volume":"32","author":"Ustun","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1182\/blood-2015-03-637728","article-title":"Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis","volume":"126","author":"Blatt","year":"2015","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.leukres.2016.02.010","article-title":"Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin","volume":"44","author":"Borate","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1182\/bloodadvances.2019000152","article-title":"A phase 2 study of brentuximab vedotin in patients with CD30-positive advanced systemic mastocytosis","volume":"3","author":"Gotlib","year":"2019","journal-title":"Blood Adv."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fmed.2017.00110","article-title":"Targeted Treatment Options in Mastocytosis","volume":"4","author":"Vaes","year":"2017","journal-title":"Front. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5626\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:32:55Z","timestamp":1760131975000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/23\/5626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,28]]},"references-count":139,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["cancers15235626"],"URL":"https:\/\/doi.org\/10.3390\/cancers15235626","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,28]]}}}